A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC - Trial NCT06294548
Access comprehensive clinical trial information for NCT06294548 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by University of Alabama at Birmingham and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 45 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Alabama at Birmingham
Timeline & Enrollment
Phase 1/2
May 31, 2024
Dec 31, 2027
Primary Outcome
Phase 1b,Phase II
Summary
This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201)
 with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did
 not receive prior systemic therapy for advanced HCC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06294548
Non-Device Trial